New cell therapy tested for Tough-to-Treat blood cancer
NCT ID NCT07476066
Summary
This early-stage study is testing an experimental cell therapy called SYS6055 in adults with aggressive B-cell lymphoma that has returned or not responded to standard treatments. The main goals are to find a safe dose, check for side effects, and see if the treatment shows early signs of helping control the cancer. Researchers will enroll about 374 participants to gather this information.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSED/REFRACTORY AGGRESSIVE B-CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
Explore the condition pages connected to this study.